Daratumumab subcutaneous formulation for the treatment of multiple myeloma. (1st November 2020)

• Record Type: Journal Article
• Authors: Paul, Barry; Hamadeh, Issam; Atrash, Shebli; Bhutani, Manisha; Voorhees, Peter; Usmani, Saad Z.
• Is Part Of: Expert opinion on biological therapy. Volume 20:Number 11(2020)
• Page Start: 1253
• Page End: 1259
• Publication Date: 2020-11-01
• Subjects: Daratumumab -- multiple myeloma -- subcutaneous; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2020.1806231
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Intravenous daratumumab has shown unprecedented anti-myeloma activity when used as a single agent or in combination with other myeloma therapies. Recently, a subcutaneous formulation of daratumumab was approved for use in both the United States and European Union based on data which showed shorter infusion times and decreased rate of infusion reactions while maintaining non-inferior efficacy. Areas covered: We cover the physiology behind subcutaneous daratumumab and summarize the relevant clinical data with a particular focus on the pharmacokinetics, pharmacodynamics, safety, and clinical efficacy. Articles used to generate this review were obtained by searching pubmed (https://pubmed.ncbi.nlm.nih.gov/ ) with the search terms 'subcutaneous daratumumab' and 'daratumumab hyaluronidase'. Expert opinion: Subcutaneous daratumumab is associated with lower risk of infusion reactions and decreased administration time while maintaining non-inferior efficacy. We support the use of subcutaneous daratumumab for all approved indications and for investigational use moving forward.